Navigation Links
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Date:1/3/2008

DEERFIELD, Ill., Jan. 3 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.

DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes, which slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretins play a major role in regulating blood glucose levels and may have the potential to improve pancreatic beta-cell function.

The NDA submission was supported by six Phase 3 clinical trials involving over 2,000 patients conducted in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other antidiabetic medications including sulfonylureas, metformin, thiazolidinediones (TZDs), and insulin. In the studies, alogliptin was associated with statistically significant reductions in hemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

"The NDA submission for alogliptin is a significant milestone for Takeda, as it has the potential to position us as one of the global leaders in diabetes treatment," said Yasuchika Hasegawa, president of Takeda. "Takeda's continued growth, now and in the future, will be based on our ability to focus and have success in this therapeutic area. Our hope is that alogliptin will become an important treat
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
3. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
4. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Indevus Announces Submission of New Drug Application
10. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wis. , Dec. 23, 2014 PuraMed ... marketer of over-the-counter (OTC) medicinal and healthcare products, announced ... of MigraPure® H, a hemp-based, advanced headache relief product, ... dispensaries in Colorado , ... . With the MigraPure H Advanced headache ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... WOONSOCKET, R.I., Dec. 11 CVS Caremark (NYSE: ... Senior Vice President and Chief Human Resources Officer, effective January ... announced his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... Caremark, has more than 30 years of human resources experience. ...
... , OXFORD, England, December 11 ... Ii Clinical Results With cat,Allergy T-cell Vaccine , ... Into,Late-Stage Development , Circassia Ltd, a ... completed a GBP15 million ($25 million),fundraising. The investment round, which ...
Cached Medicine Technology:CVS Caremark Names New Chief Human Resources Officer 2Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Residents ... Retirement Community, recently showed their generous spirit by ... the Catawba County Parenting Network- Grandparents Raising Grandchildren ... children gathered around the largest Christmas tree on ... presents purchased by residents of the Abernethy Village ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... cancer treatment center in Houston stated yesterday that ultrasound is ... cancer in pregnant woman. // ,Dr. Wei ... are hoping to educate young women that the symptomatic breast ... treated while pregnant, and so they should not wait to ...
... launched by the UK Government has been blamed for putting ... process. The Department of Health had proposed to introduce a ... 69 year olds. ,A significant delay has been ... funding and preparation, according to reports of the Cancer Research ...
... neurologist, co-director of the Muscular Dystrophy Association (MDA) ... neurology and pathology at Ohio State University College ... Program and Gene Therapy Center at Columbus Children’s ... Biopharmaceutical Inc (AskBio’s) Biostrophin, which contains a functional ...
... Kartar Singh have been sentenced to two years in jail for ... it if it was female.// This is the first time that ... determination tests and abortions. ,The perpetrators were found out ... Sabani was caught on audio and video telling one of the ...
... the heart and making a correct diagnosis cardiologists are ... students, residents, and other practicing physicians at performing a ... sounds. This was revealed by the findings of two ... ,The study was performed by Dr. Jasminka M. Vukanovic-Criley, ...
... be used for easing the debilitating pain from arthritis. // ... Shulov Institute of Sciences (SIS) in Israel where the research ... snake venom could be on sale within five years. ... most common snake in Israel - and said people suffering ...
Cached Medicine News:Health News:Delay In Life-Saving Bowel Cancer Screening Programme In UK 2Health News:Trial Of DMD Gene Therapy Initiated At Ohio 2
... The SourceLink™ Delivery System offers ... implants. It addresses the challenges associated ... as provides the flexibility of seed ... Seeds packaged per customers desired quantity ...
... EXPRESS Seeding Cartridge System is a single-use, ... seeds and spacers into a Bard BrachyStar ... has a(n): outer radiation safety shield, inner ... spacers, integrally molded fitting that connects the ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The Quinton Q-Track II Holter Monitoring System ... that produced the worlds first true 12-lead ... 12-lead presentation of any beat contained in ... analysis. , ,The preprocessing work done by ...
Medicine Products: